Douglas B. White, MD, MAS; Derek C. Angus, MD, MPH
free access
has audio
JAMA. 2020;324(4):329-330. doi:10.1001/jama.2020.11464
This Viewpoint proposes creation of state-level central lotteries for allocating drugs like remdesivir to hospitalized patients with COVID-19, which, if paired with demographic and outcome registry data, would enable equitable treatment allocation and facilitate actionable intelligence about the drugs鈥 treatment effectiveness through a natural experiment.
-
Podcast:
Remdesivir and Dexamethasone for the Treatment of COVID-19
-
Podcast:
Update on Dexamethasone for the Treatment of COVID-19
Ameet Sarpatwari, PhD, JD; Anna Kaltenboeck, MA; Aaron S. Kesselheim, MD, JD, MPH
free access
has audio
JAMA. 2020;324(4):331-332. doi:10.1001/jama.2020.11932
This Viewpoint argues that the FDA鈥檚 Emergency Use Authorization (EUA) of remdesivir missed important opportunities to mandate further study of the drug鈥檚 safety and efficacy and to require fair drug pricing, and proposes modifications to create a patient registry with required data entry for any prescription and to allow government negotiations to achieve a reasonable drug price based on shared risk-taking.
-
Podcast:
Remdesivir and Dexamethasone for the Treatment of COVID-19
-
Podcast:
Update on Dexamethasone for the Treatment of COVID-19
COVID-19: Beyond Tomorrow
J. Matthew Austin, PhD; Allen Kachalia, MD, JD
free access
JAMA. 2020;324(4):333-334. doi:10.1001/jama.2020.11461
This Viewpoint discusses deficiencies in existing approaches to measuring health care quality and safety exposed by the coronavirus disease 2019 (COVID-19) pandemic and proposes process improvements, including reducing the need for manual data extraction, reducing delays between measures and reporting, and better standardizing the measures.
COVID-19: Beyond Tomorrow
Lawrence O. Gostin, JD; Daniel A. Salmon, MPH, PhD
free access
JAMA. 2020;324(4):335-336. doi:10.1001/jama.2020.10802
This Viewpoint proposes policy responses to boost influenza vaccination uptake and reduce the anticipated morbidity and mortality of an influenza鈥揅OVID-19 co-epidemic in fall 2020.
Scott D. Halpern, MD, PhD; Robert D. Truog, MD; Franklin G. Miller, PhD
free access
JAMA. 2020;324(4):337-338. doi:10.1001/jama.2020.11623
This Viewpoint reviews common cognitive biases that led health centers and the public to favor patient- over population health鈥搊riented policy responses to the initial COVID-19 pandemic, and proposes messaging to better articulate the rationale for more effective population health responses.
Kyle H. Sheetz, MD, MSc; Nader N. Massarweh, MD, MPH
JAMA. 2020;324(4):339-340. doi:10.1001/jama.2020.2953
This Viewpoint discusses the rationale for centralizing high-risk surgical procedures鈥攔eferring patients to medical centers with more experienced surgeons to improve outcomes鈥攁nd considers alternative strategies less likely to inconvenience patients and more likely to improve surgical safety with fewer trade-offs.
Benjamin D. Horne, PhD, MStat, MPH; Martin M. Grajower, MD; Jeffrey L. Anderson, MD
has audio
JAMA. 2020;324(4):341-342. doi:10.1001/jama.2020.3908
This Viewpoint summarizes evidence about the effects of intermittent fasting on chronic disease markers and considers potential concerns about fasting as a strategy for weight management and glycemic control in people with type 2 diabetes.
-
Podcast:
Limited Evidence for the Health Effects and Safety of Intermittent Fasting in Type 2 Diabetes
Nader N. Massarweh, MD, MPH; Kamal M. F. Itani, MD; Melanie S. Morris, MD
JAMA. 2020;324(4):343-344. doi:10.1001/jama.2020.4505
In the context of loosening criteria allowing veterans cared for within the Veterans Health Administration (VHA) health system to seek and receive nonurgent care in community settings, this Viewpoint discusses comparative access and timeliness, quality, and costs associated with the VHA vs outside facility care, and potential ramifications for the US Department of Veterans Affairs (VA) budget.